



Scientific Programme

Thursday, 09 May 2019

08:00 - 09:00	Throacic Surgery Session, A4 Salle Miles Davis IX Thoracic Surgery Session 1: What's new for the pneumologist? Emphysema and tracheal disease treatment Chair: J. Plojoux (Geneva, Switzerland) Chair: D. Lardinois (Basel, Switzerland)
08:00 - 08:30	Surgical or endoscopic emphysema treatment towards a randomised trial W. Weder (Zurich, Switzerland) D. Franzen (UniversitätsSpital Zürich, Zürich, Switzerland)
08:30 - 09:00	Tracheal disease management K. Sandu (Lausanne, Switzerland)
09:00 - 10:15	Session, A4 Salle Miles Davis V Session 1: Chronic cough Chair: I. Rochat (Lausanne, Switzerland) Chair: R. Kleiner (St. Gallen, Switzerland)
09:00 - 09:25	New recommendations for children A. Möller (Zürich, Switzerland)
09:25 - 09:50	Diagnostic strategy A. Morice (Hull, United Kingdom)
09:50 - 10:15	Cough in ILD M. Funke-Chambour (Berne, Switzerland)
09:00 - 12:15	MPA Course, A3 Salle Miles Davis IV MPA Course: Fallbesprechungen Lungenfunktion
09:00 - 09:15	Begrüssung
09:15 - 10:00	Restriktive Lungenkrankheiten und deren Impact auf die Atmung M. Brutsche (St. Gallen, Switzerland)
10:00 - 10:45	Asthma bronchiale: von der Diagnose zur Therapie N. Pavlov (Bern, Switzerland)
10:45 - 11:30	Asma o BPCO? M. Bernasconi (Bellinzona, Switzerland)



Scientific Programme

11:30 - 12:15

Souffler jusqu'à l'épuisement

C. Voinea (Bellinzona, Switzerland)

09:15 - 10:15

Workshop, A4 Salle Miles Davis VI

Workshop 1: Non-CPAP treatment for OSA

09:15 - 10:15

Presentation

A.-K. Brill (Berne, Switzerland)

09:15 - 10:15

Thoracic Surgery Session, A4 Salle Miles Davis IX

Thoracic Surgery Session 2: Screening for lung cancer

Chair: M. Puhan (Epidemiology, Biostatistics und Prevention Institute, University of Zurich, Zurich, Switzerland)

Chair: R. Schmid (Berne, Switzerland)

09:15 - 09:30

View of the radiologist

K. Irion (London, United Kingdom)

09:30 - 09:35

Questions & answers

09:35 - 09:50

View of the surgeon

I. Schmitt-Opitz (Zürich, Switzerland)

09:50 - 09:55

Questions & answers

09:55 - 10:10

Caveat of lung cancer screening programmes

C. von Garnier (Bern, Switzerland)

10:10 - 10:15

Questions & answers

09:15 - 10:15

Posters, A3 Salle Miles Davis I

Poster Discussion 1: Infectious and interstitial diseases

Chair: J.-P. Janssens (HUG, Geneva, Switzerland)

Chair: A. Gazdhar (University Hospital Bern, Bern, Switzerland)

09:15 - 09:20

P01

Whole genome sequencing characterization of Isoniazid resistance mechanisms in Mycobacterium tuberculosis undetected by conventional molecular methods

O. Opota (Institute of Microbiology, University of Lausanne, University Hospital of Lausanne, Lausanne, Switzerland)

09:20 - 09:25

P02

The use of broad-range Pan-mycobacterial PCR in the diagnosis of nontuberculous mycobacteria infections: a 10-years retrospective study

O. Opota (Institute of Microbiology, University of Lausanne, University Hospital of Lausanne, Lausanne, Switzerland)



Scientific Programme

- 09:25 - 09:30 P03 Lower airway bacteria and anelloviruses reveal ecological disturbance linked to function decline in the transplanted lung**
E. Bernasconi (CHUV and STCS, Lausanne, Switzerland)
- 09:30 - 09:35 P04 Comorbidity clusters associated with length of hospital stay in patients with tuberculosis**
F. Baty (Cantonal Hospital St. Gallen, St. Gallen, Switzerland)
- 09:35 - 09:40 P05 Multidimensional genomic mapping reveals the pathophysiology of Mycobacterium abscessus**
L. Boeck (Universität Basel, Basel, Switzerland)
- 09:40 - 09:45 P06 The impact of inpatient pulmonary rehabilitation on functional independence in patients with interstitial lung disease**
S.A. Guler (University Hospital Bern (Inselspital), Bern, Switzerland)
- 09:45 - 09:50 P07 Clinical predictors to improve value of high resolution chest tomography for diagnosis of usual interstitial pneumonia pattern on histopathology**
A. Kharat (Division of Pneumology, Geneva University Hospitals, Geneva, Switzerland)
- 09:50 - 09:55 P08 Electroporation-mediated overexpression of hepatocyte growth factor results in accumulation of bone marrow mesenchymal stem cells to the injured lung**
A. Gazdhar (University Hospital Bern, Bern, Switzerland)
- 09:55 - 10:00 P09 Transcriptomic profiling of potential therapeutic target cell populations in idiopathic pulmonary fibrosis**
M. Boesch (Kantonsspital St. Gallen, St. Gallen, Switzerland)
- 10:00 - 10:05 P10 Effect of acetazolamide on pulmonary hemodynamics in COPD-patients going to altitude: a randomized trial**
M. Lichtblau (UniversitätsSpital Zürich, Zürich, Switzerland)
- 10:45 - 12:15**
Joint session, A4 Salle Miles Davis V
Joint ERS-SSP Session Congress opening: Dyspnea management
Chair: D. Adler (Hôpitaux Universitaires de Genève, Geneva, Switzerland)
Chair: L. Kern (St. Gallen, Switzerland)
- 10:45 - 11:05 The brain, both victim and guilty of the crime of breathlessness**
T. Similowski (Paris, France)
- 11:05 - 11:25 The dyspnea-inactivity vicious circle - evidence base and implications**
M. Puhan (Epidemiology, Biostatistics und Prevention Institute, University of Zurich, Zurich, Switzerland)
- 11:25 - 11:45 Quality of life in patients treated with NIV**
D. Adler (Hôpitaux Universitaires de Genève, Geneva, Switzerland)
- 11:45 - 12:05 Is it hyperventilation?**
C. Chenivesse (Lille, France)



Scientific Programme

		Workshop, A4 Salle Miles Davis VI
10:45 - 11:45		Workshop 2: New radiological criteria for IPF
10:45 - 11:45		Presentation K. Irion (London, United Kingdom)
		Thoracic Surgery Session, A4 Salle Miles Davis IX
10:45 - 12:15		Thoracic Surgery Session 3: What's new in the management of lung cancer
		Chair: F. Triponez (Geneva, Switzerland)
10:45 - 11:00		Pre-operative work-up and rehabilitation M. Licker (Geneva, Switzerland)
11:00 - 11:07		Discussion
11:07 - 11:22		ERAS M. Gonzalez (Lausanne, Switzerland)
11:22 - 11:29		Discussion
11:29 - 11:44		Immunotherapy in resectable lung cancer A. Curioni (Zürich, Switzerland)
11:44 - 11:51		Discussion
11:51 - 12:06		How to get tissue diagnosis in 2019 J. Plojoux (Geneva, Switzerland)
12:06 - 12:13		Discussion
		Posters, A3 Salle Miles Davis I
10:45 - 12:00		Poster Discussion 2: Airway and sleep diseases
		Chair: J.-M. Schnyder (Crans-Montana, Switzerland) Chair: S. Irani (Kantonsspital Aarau, Aarau, Switzerland)
10:45 - 10:50	P11	Effect of oxygen therapy on nocturnal breathing and sleep in patients with COPD travelling to high altitude. Randomized trial M. Furian (University Hospital of Zurich, Department of Respiratory Medicine, Sleep Disorders Center, Zurich, Switzerland)
10:50 - 10:55	P12	Fractionated exhaled nitric oxide is increased in viral exacerbations of COPD D. Schumann (University Hospital Basel, Basel, Switzerland)
10:55 - 11:00	P13	Exercise performance in patients with COPD at high altitude. Randomized placebo-controlled trial evaluating effects of acetazolamide M. Furian (University Hospital of Zurich, Department of Respiratory Medicine, Sleep Disorders Center, Zurich, Switzerland)



Scientific Programme

- 11:00 - 11:05 P14 Clinical characteristics of viral infections in COPD at stable state and at exacerbation**
D. Stolz (University of Basel, Basel, Switzerland)
- 11:05 - 11:10 P15 Prevention of altitude-related illness in patients with COPD by acetazolamide. Randomized, placebo-controlled trial**
M. Furian (University Hospital of Zurich, Department of Respiratory Medicine, Sleep Disorders Center, Zurich, Switzerland)
- 11:10 - 11:15 P16 Effect of preventive acetazolamide treatment on sleep-related breathing disturbances in patients with COPD staying at high altitude. Randomized trial**
M. Furian (University Hospital of Zurich, Department of Respiratory Medicine, Sleep Disorders Center, Zurich, Switzerland)
- 11:15 - 11:20 P17 Association between serum levels of glycosaminoglycans and bacterial infections in exacerbated and in stable COPD**
E. Papakonstantinou (University Hospital Basel, Basel, Switzerland)
- 11:20 - 11:25 P18 Effects of suboptimal use of CPAP-therapy on symptoms of obstructive sleep apnea: a randomized, double-blind, controlled trial**
T. Gaisl (UniversitätsSpital Zürich, Zürich, Switzerland)
- 11:25 - 11:30 P19 Prevalence of obstructive sleep apnea in patients with thoracic aortic aneurysm: a prospective, parallel cohort study**
P. Baumgartner (UniversitätsSpital Zürich, Zürich, Switzerland)
- 11:30 - 11:35 P20 Validation of NoSAS score for sleep apnea detection in a clinical sample**
S. Herschmann (CHUV, Lausanne, Switzerland)
- 11:35 - 11:40 P21 Impact of hypertension on cerebral microvascular structure in obstructive sleep apnoea patients: a diffusion magnetic-resonance imaging study**
T. Gaisl (UniversitätsSpital Zürich, Zürich, Switzerland)
- 11:40 - 11:45 P22 Neurometabolic changes during CPAP-withdrawal in obstructive sleep apnoea: data from two randomised controlled trials**
T. Gaisl (UniversitätsSpital Zürich, Zürich, Switzerland)
- 10:45 - 11:45**
Satellite Symposium, A3 Salle Miles Davis III
Satellite Atelier: The early bird catches the worm - A plea for timely initiated prostacyclins
Supported by OrPha Swiss GmbH
Chair: S. Ulrich (Zürich, Switzerland)
- 10:45 - 11:15**
Early triple therapy and the goal of low-risk status in the treatment of PAH
F. Lador (Geneva, Switzerland)
- 11:15 - 11:45**
Early prostacyclin therapy to influence vascular remodeling in PAH
A. Azzola (Lugano, Switzerland)



Scientific Programme

12:15 - 13:15

Satellite Symposium, A4 Salle Miles Davis VI

Satellite Lunch Symposium 1: Do all5s deserved our trust in severe asthma?

Supported by GlaxoSmithKline AG (GSK)

Chair: P. Howarth (GSK, University of Southampton, London, Southampton, United Kingdom)

12:15 - 12:25

Opening of the symposia

P. Howarth (GSK, University of Southampton, London, Southampton, United Kingdom)

12:25 - 12:45

Eosinophils in asthma and beyond

12:45 - 13:05

Long term efficacy and safety of all5s

13:05 - 13:15

Discussion

12:15 - 13:15

Satellite Symposium, A4 Salle Miles Davis IX

Satellite Lunch Symposium 2: ARE WE GOING THE EXTRA MILES? The patient journey toward self-management and personalized medicine in COPD & IPF

Supported by Boehringer Ingelheim (Schweiz) AG

Moderator: S.A. Guler (University Hospital Bern (Inselspital), Bern, Switzerland)
Moderator: P. Brun (Bern Reha Zentrum Heiligenschwendi, Heiligenschwendi, Switzerland)

12:15 - 12:25

Setting the Scene: The desired outcomes for a given patient

J. Bourbeau (McGill University, Montreal, Canada)

12:25 - 13:10

Patient Journey: On-stage expert discussion

J. Bourbeau (McGill University, Montreal, Canada)
C. Steurer-Stey (University Hospital Zurich, Zürich, Switzerland)
P. Brun (Bern Reha Zentrum Heiligenschwendi, Heiligenschwendi, Switzerland)
P.-O. Bridevaux (Hôpital de Sion, Sion, Switzerland)
S.A. Guler (University Hospital Bern (Inselspital), Bern, Switzerland)

13:10 - 13:15

Wrap up

12:15 - 13:15

Satellite Symposium, A3 Salle Miles Davis III

Satellite Atelier: Quality of life at life-support ventilation patients

Supported by Philips AG

Chair: R. Corbelli (HUG (Hôpital des Enfants), Geneva, Switzerland)
Chair: T. Kunze (Philips, Hamburg, Germany)



Scientific Programme

12:15 - 12:30

Welcome

M. Toscan (Philips, Zofingen, Switzerland)

12:30 - 12:45

Quality of Life at Life-Support Ventilation Patients

R. Corbelli (HUG (Hôpital des Enfants), Geneva, Switzerland)

12:45 - 13:00

Trilogy EVO - functions for maintenance the quality of life

T. Kunze (Philips, Hamburg, Germany)

13:00 - 13:15

Trilogy EVO - Hands-On

D. Puoti (Philips, Zofingen, Switzerland)

Posters, Poster exhibition Hall

12:15 - 13:15

Poster Walk 1: Airway and sleep disorders

Chair: K. Bloch (Zürich, Switzerland)

Chair: D. Adler (Hôpitaux Universitaires de Genève, Geneva, Switzerland)

P23

TNF- α reduced C/EBP- α expression by microRNA101 up-regulation in airway smooth muscle cells of COPD patients

L. Fang (University Hospital Basel, Basel, Switzerland)

P24

Serum glycosaminoglycans are differentially associated with collagen synthesis and degradation in COPD

E. Papakonstantinou (University Hospital Basel, Basel, Switzerland)

P25

Effect of preventive acetazolamide treatment on visuo-motor learning performance in lowlanders with COPD staying at high altitude. Randomized trial

P.M. Scheiwiller (University Hospital of Zurich, Department of Respiratory Medicine, Sleep Disorders Center, Zurich, Switzerland)

P26

Altitude-induced impairment in postural control in patients with COPD. Randomized, placebo-controlled trial of acetazolamide

A. Buergin (University Hospital of Zurich, Department of Respiratory Medicine, Sleep Disorders Center, Zurich, Switzerland)

P27

The course of handgrip strength is no indicator for mortality in COPD: a longitudinal cohort study

D. Kohlbrenner (University Hospital Zurich, Zurich, Switzerland)

P28

Swiss Severe Asthma Register (SAR)

V. Mangold (Kantonsspital, Liestal, Switzerland)

P29

Improvement in self-reported physical functioning with tiotropium/olodaterol in a subgroup of Swiss COPD patients participating in a large international trial

D. Schumann (University Hospital Basel, Basel, Switzerland)

P30

Multi-walled carbon nanotubes activate and shift polarization of pulmonary macrophages and dendritic cells in an in vivo model of COPD

F. Blank (University Hospital Bern (Inselspital), Bern, Switzerland)



Scientific Programme

- P31** **Early spirometry after bronchoscopic lung volume reduction with endobronchial valves**
P. Bezel (University Hospital Zurich, Zürich, Switzerland)
- P32** **Efficacy of pharmacotherapy for obstructive sleep apnea in adults: a systematic review and network meta-analysis**
T. Gaisl (UniversitätsSpital Zürich, Zürich, Switzerland)
- P33** **Effects of CPAP treatment on sex hormone levels in obstructive sleep apnoea patients - data from two randomised, controlled trials**
F. Grewe (UniversitätsSpital Zürich, Zürich, Switzerland)
- P34** **The Geneva Lake study update: a descriptive and cross-sectional multicentric study of long-term home non-invasive ventilation: deceased population**
C. Cantero (Geneva University Hospitals, Geneva, Switzerland)
- P35** **Prediction of sleep apnea severity using a portable electrocardiogram monitoring device**
F. Baty (Cantonal Hospital St. Gallen, St. Gallen, Switzerland)
- P36** **Changing from oronasal to nasalpillow mask may lower CPAP pressure and improve AHI and adherence in CPAP-therapy more than expected**
T. Schmid (Lungenpraxis Stadtgarten Solothurn, Solothurn, Switzerland)
- P37** **Anatomical segmentectomy for lung volume reduction surgery after endoscopic coils insertion**
J. Martin (CHUV, Lausanne, Switzerland)
- P38** **Clinical presentation and cardiovascular consequences of OSA-COPD overlap syndrome**
D. Adler (Hôpitaux Universitaires de Genève, Geneva, Switzerland)

Posters, Poster exhibition Hall

12:15 - 13:15

Poster Walk 2: Infection and pulmonary vascular disease

Chair: A. Azzola (Lugano, Switzerland)
Chair: J. Mazza-Stalder (Lausanne, Switzerland)

- P39** **Clinical impact of a multiplex bacterial PCR of bronchoalveolar lavage in patients with suspected lower respiratory tract infection**
A. Salina (University Hospital Basel, Basel, Switzerland)
- P40** **High prevalence of peribronchial focal lesions of airway invasive aspergillosis in prolonged neutropenic hematological cancer patients**
A. Casutt (CHUV, Lausanne, Switzerland)
- P41** **Whole genome sequencing for rapid, reliable and routine investigation of Mycobacterium tuberculosis transmission in local communities**
J. Mazza-Stalder (Lausanne, Switzerland)
- P42** **Hide and seek: repeated bronchoscopy in nonresolving pneumonia**
N. Pavlov (Bern, Switzerland)



Scientific Programme

- P43 DLCO as a marker of severity in pulmonary hypertension**
E. Diamanti (CHUV, Lausanne, Switzerland)
- P44 Internal validation of MRI flow quantification and correlation to Fick and thermodilution catheterization-derived cardiac output**
F. Lador (Geneva, Switzerland)
- P45 Daily activity in incident patients with pulmonary hypertension is not correlated to hemodynamics but walk distance**
S. Saxer (UniversitätsSpital Zürich, Zürich, Switzerland)
- P46 Validity of invasive and noninvasive methods for determination of cardiac output in pulmonary hypertension**
L. Genecand (Hôpitaux Universitaires de Genève, Programme Hypertension Pulmonaire, Genève, Switzerland)
- P47 Right heart catheterization hemodynamics at rest and exercise in supine versus upright position with focus on pulmonary hypertension**
C. Berlier (University Hospital of Zurich, Zurich, Switzerland)
- P48 Pulmonary tumor thrombotic microangiopathy: unusual diagnosis from right heart catheterisation**
F. Lador (Geneva, Switzerland)
- P49 Case report: pulmonary arterial hypertension due to congenital heart disease - think of it in adults!**
M. Lichtblau (UniversitätsSpital Zürich, Zürich, Switzerland)
- P50 Comparison of intrapleural use of urokinase and t-PA/DNase in pleural infection**
W. Karenovics (Geneva, Switzerland)

Posters, Poster exhibition Hall

12:15 - 13:15

Poster Walk 3: Interstitial and vascular disorders & cancer

Chair: R. Lazor (Lausanne, Switzerland)

Chair: C. Clarenbach (University Hospital Zurich, Zurich, Switzerland)

- P51 Anti-fibrotic and apoptotic effects of Azithromycin in IPF and control lung fibroblasts**
K. Krempaska (University of Bern, Bern, Switzerland)
- P52 Standardized home inspection in search of antigen exposure in chronic hypersensitivity pneumonitis**
C. Daccord (Lausanne University Hospital, Lausanne, Switzerland)
- P53 Thoracic imaging in primary ciliary dyskinesia**
C. Daccord (Lausanne University Hospital, Lausanne, Switzerland)
- P54 New comprehensive PCD diagnostics at the "Interdisciplinary PCD diagnostic center PCD-UNIBE"**
L. Müller (Bern University Hospital, University of Bern, Bern, Switzerland)



Scientific Programme

- P55 Immunotherapy-induced bronchitis/bronchiolitis: a new pattern of lung toxicity of immune checkpoint inhibitors**
G. Mitropoulou (Lausanne University Hospital - CHUV, Lausanne, Switzerland)
- P56 A single academic centre experience in lung cryobiopsies for the workup of interstitial lung disease**
A. Kharat (Division of Pneumology, Geneva University Hospitals, Geneva, Switzerland)
- P57 Cisplatin-resistant non-small cell lung cancer cells are characterized by high levels of mitochondrial mass and are susceptible to pemetrexed treatment**
T.M. Marti (Inselspital, Bern University Hospital, Switzerland, Bern, Switzerland)
- P58 Does rapid on-site cytologic evaluation during EBUS-guided transbronchial needle aspiration reduce the need for transbronchial biopsy in sarcoidosis?**
M. Kolb (Division of Lung Diseases, Geneva University Hospitals, Geneva, Switzerland)
- P59 Electromagnetic navigation bronchoscopy for peripheral nodules**
K. Jahn (University Hospital Basel, Basel, Switzerland)
- P60 Positron emission tomography-computed tomography (PET-CT) scan in evaluation of microwave ablation therapy**
S. Saenghirunvattana (Bangkok Hospital Medical Center, Bangkok Dusit Medical Services, Bangkok, Thailand)
- P61 mTOR inhibition in combination with chemotherapy is a rational strategy to treat KRAS-mutant lung cancer**
R.-W. Peng (Division of General Thoracic Surgery, Department for BioMedical Research (DBMR), Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland)
- P62 Early detection and resection of lung cancer by electromagnetic navigation bronchoscopy with dye-marking**
S. Saenghirunvattana (Bangkok Hospital Medical Center, Bangkok Dusit Medical Services, Bangkok, Thailand)
- P63 Congenital alveolar dysplasia**
S. Guérin (CHUV, Lausanne, Switzerland)

Posters, Poster exhibition Hall

12:15 - 13:15

Poster Walk 4: Prevention, diagnostic techniques, clinical pearls

Chair: A.-K. Brill (Berne, Switzerland)

Chair: J.F. Vodoz (spéc. FMH en médecine interne et en pneumologie, Montreux, Switzerland)

- P64 Text mining – a tool for quality assessment of medical records**
J. Hegermann (Cantonal Hospital St. Gallen, St. Gallen, Switzerland)



Scientific Programme

- P65 Transition from pediatric to adult center in cystic fibrosis: which consequences for the patients?**
M. Prella (CHUV, Lausanne, Switzerland)
- P66 Information, content marketing, official communication around E-cigarette Juul's introduction into the swiss market**
R. Kaelin (Morges, Switzerland)
- P67 A case of microwave ablation of lung tumor in a patient with implanted pacemaker**
S. Saenghirunvattana (Bangkok Hospital Medical Center, Bangkok Dusit Medical Services, Bangkok, Thailand)
- P68 Validation of a portable blood gas analyzer (EPOC Siemens) for use in challenging field conditions**
J. Nawrocki (University Hospital of Zurich, Department of Respiratory Medicine, Sleep Disorders Center, Zurich, Switzerland)
- P69 OxyFrame: validation of an ear pulse oximeter for integration into eye glasses frames**
M. Funke-Chambour (Berne, Switzerland)
- P70 Thoracoscopic segmentectomy on ECMO to manage a second primary lung cancer in a patient with a prior left pneumonectomy**
E. Koliakos (Centre Hospitalier Du Valais Romand, Sion, Switzerland)
- P71 Postoperative lingula segment torsion after multi-segmentectomy: a case report**
R. Bumm (Klinik für Thoraxchirurgie, Kantonsspital, Graubünden, Switzerland)
- P72 Anastomosing hemangioma of the posterior mediastinum: a case report and review of the literature**
S. Federici (Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland)

Thoracic Surgery Session, A3 Salle Miles Davis I

13:00 - 14:15

Thoracic Surgery Session 4: Free Communications

Chair: F. Triponez (Geneva, Switzerland)

Chair: D. Franzen (UniversitätsSpital Zürich, Zürich, Switzerland)

13:00 - 13:12

Outcomes of patients discharged home with a chest tube following anatomical lung resection: a multicenter cohort study

F. Minervini (Luzerner Kantonsspital, Lucerne, Switzerland)

13:12 - 13:24

The impact of patient compliance and individual components in an ERAS pathway on the outcome of anatomical VATS resections

C. Forster (Lausanne University Hospital, Lausanne, Switzerland)

13:24 - 13:36

Uniportal thoracoscopic anatomic segmentectomy: clinical and oncological outcome of 150 cases

K. Gioutsos (Inselspital, Bern University Hospital, Switzerland, Bern, Switzerland)



Scientific Programme

- 13:36 - 13:48** **Chest wall resections and reconstructions for malignant diseases: a single center experience in 158 cases**
L. Elahi-Rausis (Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland)
- 13:48 - 14:00** **Outcome of incidental and secondary bronchogenic carcinoma following lung transplantation**
C. Forster (Lausanne University Hospital, Lausanne, Switzerland)
- 14:00 - 14:12** **Clinical outcome of loculated parapneumonic effusions managed surgically or by intrapleural fibrinolysis: a comparative multicenter study**
S. Federici (Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland)
- 13:00 - 14:00** MPA Course, A3 Salle Miles Davis IV
Generalversammlung Vereinigung der Lungenfunktionsmitarbeitenden
- 13:15 - 14:15** Session, A4 Salle Miles Davis V
Session 2: PAH in chronic respiratory diseases
Chair: J. Pichler Hefti (Berne, Switzerland)
Chair: F. Lador (Geneva, Switzerland)
- 13:15 - 13:35** **PH in COPD**
J.A. Barberà (Barcelona, Spain)
- 13:35 - 13:55** **PH and SOAS: is there a link?**
K. Bloch (Zürich, Switzerland)
- 13:55 - 14:15** **Diagnostic and therapeutic tools provided by the radiologist in PH**
S. Qanadli (CHUV, Lausanne, Switzerland)
- 13:15 - 14:45** Paediatric Pulmology Session, A4 Salle Miles Davis IX
Paediatric Grand Rounds
Chair: D. Müller-Suter (Arrau, Switzerland)
Chair: N. Regamey (Luzern, Switzerland)
- 13:15 - 13:30** **3-year old child with cyanosis**
P. Lorenz (Children's Hospital, St. Gallen, St. Gallen, Switzerland)
- 13:30 - 13:45** **Careful examination of the family doctor as key to an early diagnosis of a rare disease**
C. Abbas (University Children's Hospital, Berne, Switzerland)



Scientific Programme

- 13:45 - 14:00** **Infant with life-threatening laryngotracheobronchomalacia**
J. Usemann (University Children's Hospital, Zurich, Switzerland)
- 14:00 - 14:15** **Non-resolving pneumonia in an adolescent**
K. Hoyler-Uhlmann (Children's Hospital Lucerne, Lucerne, Switzerland)
- 14:15 - 14:30** **Congenital Alveolar Dysplasia**
S. Guérin (CHUV, Lausanne, Switzerland)
- 14:30 - 14:45** **Atypical pneumonia or an unsuspected culprit?**
A. Jochmann (University Children's Hospital, Basel, Switzerland)
- 13:30 - 14:30** **Satellite Symposium, A4 Salle Miles Davis VI**
Satellite Symposium 3: ICS in COPD - A never ending question?
Supported by: Novartis Pharma Schweiz AG
Chair: J.-P. Janssens (HUG, Geneva, Switzerland)
- 13:30 - 13:40** **Welcome speech**
J.-P. Janssens (HUG, Geneva, Switzerland)
- 13:40 - 13:50** **ICS, does it really fit to all patients?**
H. Magnussen (Klinikum Stephanplatz, Hamburg, Germany)
- 13:50 - 14:00** **ICS, what's the price the patients have to pay?**
J.L. Lopez-Campos (Hospital Universitario Virgen del Rocío, Seville, Spain)
- 14:00 - 14:30** **Discussion**
J.-P. Janssens (HUG, Geneva, Switzerland)
H. Magnussen (Klinikum Stephanplatz, Hamburg, Germany)
J.L. Lopez-Campos (Hospital Universitario Virgen del Rocío, Seville, Spain)
A. Turk (Seespital, Horgen, Switzerland)
- 14:15 - 16:00** **MPA Course, A3 Salle Miles Davis IV**
MPA/MTA Course: Pléthysmographie corporelle et mesure des résistances - formation pratique (public cible pneumologue et techniciens)
The course will be held in French. Maximum capacity: 15 pax. This session need to be booked via the registration platform.
- 14:15 - 16:00** **Presentation**
N. Petitpierre (Lausanne, Switzerland)
E. Aubry (Lausanne, Switzerland)



Scientific Programme

- Joint session, A4 Salle Miles Davis V
- 14:30 - 16:00** **Joint ERS-SSP Session 2: Pulmonary fibrosis**
Chair: K. Hostettler Haack (University Hospital Basel, Basel, Switzerland)
Chair: M. Funke-Chambour (Berne, Switzerland)
- 14:30 - 15:00** **New IPF diagnostic criteria: ATS/ERS and Fleischner Society Position Papers**
L. Richeldi (A. Gemelli University Hospital - IRCCS, Rome, Italy)
- 15:00 - 15:30** **IPF and lung cancer**
A. Prasse (Hannover, Germany)
- 15:30 - 16:00** **Cryobiopsies - when, where, how, who doing it?**
J. Hetzel (Tübingen, Germany)
- Workshop, A3 Salle Miles Davis I
- 14:30 - 16:00** **Workshop 3: Analgosedation**
Chair: D. Franzen (UniversitätsSpital Zürich, Zürich, Switzerland)
Chair: T. Schneider (St. Gallen, Switzerland)
- 14:30 - 14:35** **Begrüssung**
D. Franzen (UniversitätsSpital Zürich, Zürich, Switzerland)
- 14:35 - 14:50** **Pharmakologie**
S. Kraye (Zurich, Switzerland)
- 14:50 - 15:05** **Sedierungsmethoden und Studienlage in der Pneumologie**
K. Jahn (University Hospital Basel, Basel, Switzerland)
- 15:05 - 15:20** **Zwischenfallmanagement**
D. Franzen (UniversitätsSpital Zürich, Zürich, Switzerland)
S. Kraye (Zurich, Switzerland)
- 15:20 - 15:35** **Risikoabschätzung und besondere Risiken im pneumologischen Patientengut**
K. Jahn (University Hospital Basel, Basel, Switzerland)
- 15:35 - 15:50** **Politischer/juristischer Background, Schweizerische Empfehlungen**
S. Kraye (Zurich, Switzerland)
D. Franzen (UniversitätsSpital Zürich, Zürich, Switzerland)
- 15:50 - 16:00** **Praktische Tipps: - Patientenmonitoring - Infusionsleitungen - Pumpendemonstration**
S. Kraye (Zurich, Switzerland)



Scientific Programme

15:00 - 16:00

Satellite Symposium, A4 Salle Miles Davis VI

Satellite Symposium 4: Strategies in PAH to optimize patient outcomes

Supported by MSD Merck Sharp & Dohme AG

Chair: S. Ulrich (Zürich, Switzerland)

15:00 - 15:30

How new technologies support you in your clinical practice

F. Lador (Geneva, Switzerland)

15:30 - 16:00

PAH patient cases - value of risk assessment

S. Rosenkranz (Cologne, Germany)

15:00 - 16:00

Workshop, A4 Salle Miles Davis IX

Workshop 4: CF evidence-based treatments

15:00 - 16:00

Presentation

A. Mornand (Geneva, Switzerland)

F. Singer (Bern, Switzerland)

16:30 - 18:00

Session, A4 Salle Miles Davis V

Session 3: Sleep disorders for the pulmonologist

Chair: A.-K. Brill (Berne, Switzerland)

Chair: O. Schoch (St.Gallen, Switzerland)

16:30 - 17:00

Sleep apnea: fitness to drive

J. Mathis (Berne, Switzerland)

17:00 - 17:30

Phenotyping obstructive sleep apnea - clinical implications

M. Kohler (Zürich, Switzerland)

17:30 - 18:00

Sleep apnea in non-sleepy patients and sleepy patients without sleep apnea

R. Heinzer (Lausanne, Switzerland)

16:30 - 18:00

Session, A4 Salle Miles Davis VI

Session 4: Lung health prevention

Chair: M. Schuurmans (Winterthur, Switzerland)

Chair: R. Kaelin (Morges, Switzerland)

16:30 - 16:50

Air pollution: threshold values for small particles and health impact

N. Künzli (Basel, Switzerland)



Scientific Programme

- 16:50 - 17:10** **Expected health-related outcomes with vaporizers (E-cigarettes) for smoking cessation**
R. Auer (Berne, Switzerland)
- 17:10 - 17:30** **Immunization for prevention of infectious lung diseases**
A. Diana (Geneva, Switzerland)
- 17:30 - 17:50** **Professional exposure and lung disease practical approach**
J. Pralong (Lausanne, Switzerland)
- 17:50 - 18:00** **Discussion**
- 16:30 - 17:30** Workshop, A4 Salle Miles Davis IX
Workshop 5: Ambulatory management of patient with pleural disease
- 16:30 - 17:30** **Presentation**
P. Kestenholz (Luzern, Switzerland)
T. Schneider (St. Gallen, Switzerland)
- 16:30 - 17:30** Satellite Symposium, A3 Salle Miles Davis III
Satellite Atelier: IPF - How do experts differentiate from other ILDS - a practical approach
supported by Boehringer Ingelheim (Schweiz) GmbH
Moderator: L. Richeldi (A. Gemelli University Hospital - IRCCS, Rome, Italy)
Moderator: J.-M. Fellrath (Neuchâtel, Switzerland)
Moderator: K. Hostettler Haack (University Hospital Basel, Basel, Switzerland)
- 16:30 - 16:50** **Diagnosing IPF: Translation of new guidelines into daily routine**
- 16:50 - 17:10** **Distinguish IPF from other ILDS: Helpful tools and methods**
- 17:10 - 17:30** **Frequently asked questions (FAQs): Ask the experts**
- 16:30 - 18:00** MPA Course, A3 Salle Miles Davis IV
MPA/MTA Course: Bodyplethysmographie und Resistenzmessung - Hands on für Pneumologen MPA/MTA
The course will be held in German. Maximum capacity: 15 pax. This session need to be booked via the registration platform.
- 16:30 - 18:00** **Presentation**
J. Leuppi (Liestal, Switzerland)
M. Leuenberger (St. Gallen, Switzerland)



Scientific Programme

17:30 - 18:15

Assembly, A4 Salle Miles Davis IX

SIG Assembly: Interstitial and Rare Lung Diseases

17:30 - 18:15

Assembly, A3 Salle Miles Davis III

SIG Assembly: Functional Diagnostics

18:15 - 19:45

Assembly, A4 Salle Miles Davis V

General Assembly SGP/SSP



Scientific Programme

Friday, 10 May 2019

08:00 - 08:45	Assembly, A4 Salle Miles Davis V SIG Assembly: Ventilation & O2
08:00 - 08:45	Assembly, A4 Salle Miles Davis VI SIG Assembly: Pulmonary Vascular Disease
08:00 - 09:00	Workshop, A4 Salle Miles Davis IX Workshop 6: Lung function practical cases
08:00 - 09:00	Presentation P.-O. Bridevaux (Hôpital de Sion, Sion, Switzerland)
08:00 - 09:00	Satellite Symposium, A3 Salle Miles Davis III Satellite Atelier: Boehringer Ingelheim INHALEABILITY- RESPIRATORY DRUG DELIVERY What you always wanted to know about inhalers
08:00 - 08:20	Moderator: M. Brutsche (St. Gallen, Switzerland) Does device choice really matter?
	H. Wachtel (Mainz University and Boehringer Ingelheim, Germany)
08:20 - 08:40	Goals of COPD treatment: Let's start with the patient
	H. Wachtel (Mainz University and Boehringer Ingelheim, Germany)
08:40 - 09:00	Demonstration: how do we do and how should we do
	H. Wachtel (Mainz University and Boehringer Ingelheim, Germany)
08:00 - 09:00	Workshop, A3 Salle Miles Davis IV Workshop 7: Nodule Management
08:00 - 08:30	Lung nodule management
	A. Lovis (Lausanne, Switzerland)
08:30 - 09:00	Lung nodule management
	T. Krueger (Lausanne, Switzerland)



Scientific Programme

	Joint session, A4 Salle Miles Davis V
09:00 - 10:30	Joint ERS-SSP Session 3: Pulmonary rehabilitation Chair: C. Steurer-Stey (University Hospital Zurich, Zürich, Switzerland) Chair: I. Frésard (Sion, Switzerland)
09:00 - 09:20	Personalized rehabilitation for my patient with chronic lung disease M.A. Spruit (Horn/Maastricht, Netherlands)
09:20 - 09:40	Rehabilitation in IPF patients P. Brun (Berner Reha Zentrum Heiligenschwendi, Heiligenschwendi, Switzerland)
09:40 - 10:00	Disease management programme in COPD J. Bourbeau (McGill University, Montreal, Canada)
10:00 - 10:20	Preoperative rehabilitation P.-O. Bridevaux (Hôpital de Sion, Sion, Switzerland)
10:20 - 10:30	Questions & answers
	Satellite Symposium, A4 Salle Miles Davis VI
09:00 - 10:00	Satellite Symposium 5: Vertex Pharmaceuticals (CH) GmbH (How) Can we predict response to CFTR modulators? Chair: A. Sauty (Lausanne, Switzerland)
09:00 - 09:05	Welcome and introduction: What does «Residual Function» mean? What is «Minimal Function»? A. Sauty (Lausanne, Switzerland)
09:05 - 09:20	In vitro and ex vivo models to predict response to CFTR modulators in CF M. Chanson (Switzerland)
09:20 - 09:35	What do we know from sweat chloride and response to CFTR modulators? A. Sauty (Lausanne, Switzerland)
09:35 - 09:50	What do we know from lung function and prediction of response to CFTR modulators? P. Latzin (Berne, Switzerland)
09:50 - 10:00	Discussion and end A. Sauty (Lausanne, Switzerland)



Scientific Programme

- Session, A4 Salle Miles Davis IX
- 09:15 - 10:30** **Session 5: Update and new treatment of asthma**
supported by an unrestricted educational grant from Astra Zeneca AG This session is organised by the scientific committee. The industry partners are kindly supporting the programme without any influence on topic, content and speakers.
Chair: L. Nicod (Lausanne, Switzerland)
Chair: J. Leuppi (Liestal, Switzerland)
- 09:15 - 09:40** **Biologicals in asthma: an update**
F. Chung (London, United Kingdom)
- 09:40 - 10:05** **Are there still indications for bronchial thermoplasty in the era of biologicals for asthma?**
D. Stolz (University of Basel, Basel, Switzerland)
- 10:05 - 10:30** **Biologicals in non asthmatic lung diseases**
F. Roufosse (Bruxelles, Belgium)
- Paediatric Pulmology Session, A3 Salle Miles Davis IV
- 09:15 - 10:30** **Paediatric Pulmonary Scientific Session 1: Free Communications**
Chair: C. Barazzone-Argiroffo (Geneva, Switzerland)
Chair: F. Singer (Bern, Switzerland)
- 09:15 - 09:30** **The skin microbiome drives immune maturation and exacerbation of both skin and airway inflammation**
N. Ubags (CHUV, Lausanne, Switzerland)
- 09:30 - 09:45** **Exposure to moderate air pollution and associations with lung function at school-age: a birth cohort study**
J. Usemann (University Children's Hospital, Zurich, Switzerland)
- 09:45 - 10:00** **Pulmonary late effects after hematopoietic stem cell transplantation in childhood cancer survivors in Switzerland**
M. Otth (Institute of Social and Preventive Medicine, Bern, Switzerland)
- 10:00 - 10:15** **CD90 identifies a distinct pulmonary mesenchymal cell subtype with both immune modulatory and perivascular-like function in postnatal human lung**
S. Hall (Inselspital, Bern University Hospital, Bern, Switzerland)
- 10:15 - 10:30** **MUCOVIB: Cystic fibrosis, respiratory viruses and intracellular bacteria: preliminary results of a pediatric collaborative study VAUD/GE**
S. Asner (Switzerland)



Scientific Programme

- 09:30 - 10:30 Satellite Symposium, A3 Salle Miles Davis III
Satellite Atelier: Actelion Pharma Schweiz AG Practical management of PAH - interactive patient cases
Chair: S. Ulrich (Zürich, Switzerland)
Chair: J.-D. Aubert (Lausanne, Switzerland)
- 09:30 - 10:30 **Practical management of PAH - interactive patient cases**
D. Kiely (Sheffield Pulmonary Vascular Disease Unit at the Royal Hallamshire Hospital, Sheffield, United Kingdom)
- 11:00 - 12:30 Session, A4 Salle Miles Davis V
Session 6: Swiss Pulmonary Challenge
Chair: K. Bloch (Zürich, Switzerland)
Chair: T. Brack (Glarus, Switzerland)
- 11:00 - 12:00 Satellite Symposium, A4 Salle Miles Davis VI
Satellite Symposium 6: Relevance of the small airways disease
Supported by: Vifor Pharma (OM Pharma Switzerland)
Chair: D. Stolz (University of Basel, Basel, Switzerland)
- 11:00 - 11:15 **Revisiting the small airways disease in asthma and COPD**
D. Stolz (University of Basel, Basel, Switzerland)
- 11:15 - 11:55 **Advances in treatment of the small airways disease in asthma and COPD**
D. Singh (University of Manchester, Manchester, United Kingdom)
- 11:55 - 12:00 **Questions & answers**
- 11:00 - 12:30 Session, A4 Salle Miles Davis IX
Session 7: Rare respiratory diseases
Chair: R. Lazor (Lausanne, Switzerland)
Chair: T. Geiser (Inselspital, Bern, Switzerland)
- 11:00 - 11:25 **Histiocytosis X**
A. Tazi (Paris, France)
- 11:25 - 11:33 **Questions & answers**
- 11:33 - 11:58 **IPF Drugs for Non IPF Diseases**
A. Prasse (Hannover, Germany)
- 11:58 - 12:06 **Questions & answers**



Scientific Programme

12:06 - 12:21 **Screening for alpha-1 PI deficiency in COPD: apractical approach**
T. Greulich (Marburg, Germany)

12:21 - 12:29 **Questions & answers**

11:00 - 12:00 **Satellite Atelier: Treating the COPD Patient - between guidelines, biomarkers and practice routine**

Satellite Symposium, A3 Salle Miles Davis III

Supported by: GlaxoSmithKline AG GSK

11:00 - 11:05

Chair: P. Jones (GSK, London, United Kingdom)
Chair: C. Clarenbach (University Hospital Zurich, Zurich, Switzerland)

Welcome & introduction

C. Clarenbach (University Hospital Zurich, Zurich, Switzerland)
P. Jones (GSK, London, United Kingdom)

11:05 - 11:12

COPD - Recent guidelines update & Swiss practice in 2019

C. Clarenbach (University Hospital Zurich, Zurich, Switzerland)

11:12 - 11:20

Biomarkers in COPD - What does recent evidence tell us?

P. Jones (GSK, London, United Kingdom)

11:20 - 11:55

Roundtable discussions: Guidelines, biomarkers and practice routine - how to join the dots for a more personalised treatment?

P. Jones (GSK, London, United Kingdom)
C. Clarenbach (University Hospital Zurich, Zurich, Switzerland)

11:55 - 12:00

Wrap-up & closure

P. Jones (GSK, London, United Kingdom)
C. Clarenbach (University Hospital Zurich, Zurich, Switzerland)

11:00 - 12:30

Session, A3 Salle Miles Davis IV

Top ranked respiratory research in Switzerland (Swiss Lung Association)

Chair: C. Barazzone-Argiroffo (Geneva, Switzerland)
Chair: M. Tamm (Basel, Switzerland)

11:00 - 11:10

Introduction and presentation of the FOFO

C. Barazzone-Argiroffo (Geneva, Switzerland)



Scientific Programme

- 11:10 - 11:25** **Award Handover Presentation of the winning project**
C. Barazzone-Argiroffo (Geneva, Switzerland)
A. Trompette (Switzerland)
- 11:25 - 11:35** **Effect of a long-term home-based exercise training using minimal equipment vs. usual care in COPD patients: A multicentre randomized controlled trial**
A. Frei (Zürich, Switzerland)
- 11:35 - 11:45** **Assessment of novel therapeutic strategies for the treatment of allergic asthma**
A. Eggel (Switzerland)
- 11:45 - 11:55** **Molecular regulation of innate lymphoid cell type 2 in lung disease**
P. Krebs (Switzerland)
- 11:55 - 12:05** **Fluctuation dynamics of biomarkers to predict exacerbations in asthma: A stepping stone for early intervention**
A. Sinha (Switzerland)
- 12:05 - 12:15** **Effect of Hepatocyte growth factor on regulatory T cells in bleomycin injured rat lung**
S. Mutlu (Switzerland)
- 12:15 - 12:25** **Role of bacterial communities in infants with cystic fibrosis**
M. Hilty (Switzerland)
- 12:30 - 13:30** Satellite Symposium, A4 Salle Miles Davis VI
Satellite Lunch Symposium 7: Making a difference in Asthma
supported by Astra Zeneca AG
Chair: P.-O. Bridevaux (Hôpital de Sion, Sion, Switzerland)
- 12:30 - 13:00** **Overdiagnosis of asthma**
A. Bourdin (Montpellier, France)
- 13:00 - 13:30** **OCS use along the asthma continuum**
A. Bourdin (Montpellier, France)
- 12:30 - 13:15** Assembly, A4 Salle Miles Davis IX
SIG Assembly: Sleep Breathing Disorders



Scientific Programme

12:30 - 13:30	Session, A3 Salle Miles Davis III Session 8: Prevention (tobacco/environment) Chair: A. Zürcher (Uster, Switzerland) Chair: M. Schuurmans (Winterthur, Switzerland)
12:30 - 13:00	E-cigarettes, Swiss Youth and the tobacco epidemic J. Barben (St. Gallen, Switzerland)
13:00 - 13:30	Promoting Tobacco by the proposed federal Tobacco product law R. Kaelin (Morges, Switzerland)
12:30 - 14:00	Assembly, A3 Salle Miles Davis IV General Assembly SSPP
13:30 - 14:15	Assembly, A4 Salle Miles Davis V SIG Assembly: Obstructive Lung Disease
13:30 - 14:15	Assembly, A4 Salle Miles Davis VI SIG Assembly: Prevention (tobacco/environment)
13:30 - 14:30	Session, A4 Salle Miles Davis IX Session 9: Pulmonary embolism Chair: A. Azzola (Lugano, Switzerland) Chair: S. Ulrich (Zürich, Switzerland)
13:30 - 13:50	Risk stratification for acute PE L. Mazzolai (Lausanne, Switzerland)
13:50 - 14:10	Unprovoked pulmonary embolism: silent diseases to look at? S. Ulrich (Zürich, Switzerland)
14:10 - 14:30	Ambulatory follow up after PE: What the pulmonologist should know F. Lador (Geneva, Switzerland)
13:30 - 17:00	Workshop, A3 Salle Miles Davis III Training: TARMED 1.08 BR "Lesson to learn" (Deutsch) The course will be held in German. Maximum capacity: 25 pax. This session need to be booked via the registration platform.



Scientific Programme

14:30 - 16:00	Session, A4 Salle Miles Davis V Session 10: President's lecture incl. TB-Prize and awards ceremony Chair: L. Nicod (Lausanne, Switzerland)
14:30 - 15:20	Early life origin of adult diseases A. Agusti (Barcelona, Spain)
15:20 - 15:30	Award Ceremony: TB-Prize L. Nicod (Lausanne, Switzerland) O. Brändli (Wald, Switzerland)
15:30 - 15:40	Award Ceremony: Prize for Swiss Pulmonary Challenge K. Bloch (Zürich, Switzerland)
15:40 - 15:50	Award Ceremony: Swiss Lung Association C. Barazzone-Argiroffo (Geneva, Switzerland)
15:50 - 16:00	Award Ceremony: Poster-Prize J.-D. Aubert (Lausanne, Switzerland)
14:30 - 15:30	Workshop, A4 Salle Miles Davis VI Workshop 8: Tobacco cessation programme
14:30 - 15:30	Presentation A. Meienberg (Basel, Switzerland) U. Engler (Basel, Switzerland)
14:30 - 15:30	Paediatric Pulmology Session, A4 Salle Miles Davis IX Paediatric Pulmonary Scientific Session 2: Update on Primary Ciliary Dyskinesia (and not non CF bronchiectasis) Chair: C. Daccord (Lausanne University Hospital, Lausanne, Switzerland) Chair: A. Jung (Zürich, Switzerland)
14:30 - 14:50	Epidemiology of PCD - improving data on a rare disease C. Kühni (Berne, Switzerland)
14:50 - 15:10	Current diagnostic approaches and implementation in Switzerland P. Latzin (Berne, Switzerland)
15:10 - 15:30	New insights on genetic and microscopic diagnostic on PCD S. Blanchon (Lausanne, Switzerland)